Lipid profile and concentration of ApoA-1 and ApoB-100 in patients with end-stage renal disease treated by repeated haemodialysis.

Lipid metabolism disorders in patients with end-stage renal disease, particularly in patients with nephrotic syndrome, were described by Dr Bright as long ago as 1827 [1]. It is known that patients with end-stage renal disease (ESRD) display a clinical picture of early accelerated (premature) atherosclerosis with severe cardiovascular and cerebral complications that are very often present even at a relatively early age compared with the general population. Today, it is considered that uraemic dyslipidaemia has persisted for many years before chronic dialysis treatment begins and presents a basic risk factor for an early start of the atherogenesic processes.